J. & C.S. DEVELOPMENTS LIMITED
Company number 05327457 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Score: C (Fair / Guarded)
The company is solvent and meets its filing obligations, but its equity base has contracted sharply and it carries substantial secured debt relative to shareholders’ funds. Short-term liquidity remains adequate, yet the trend in net assets and creditor behaviour suggests financial strain that warrants close monitoring.
Key Vital Signs
1. Solvency — Net Assets / Shareholders’ Funds - 2025: £25,269 | 2024: £118,628 - Interpretation: This is the company’s financial cushion after all debts are paid. It fell by roughly £93,000 (about 79%) in a single year. A positive balance means the company is not technically insolvent, but the rapid erosion is a significant warning sign, similar to rapid loss of body mass in a patient.
2. Short-Term Liquidity — Current Ratio - 2025: 1.90 | 2024: 3.05 - Calculation: Current assets ÷ current creditors due within one year. - Interpretation: The company can cover its short-term obligations about 1.9 times over. This is still healthy, but the decline from 3.05 shows the buffer is thinning. A ratio below 1.0 would be akin to a dangerously low pulse.
3. Cash Position - 2025: £125,040 | 2024: £85,374 | 2023: £468,587 - Interpretation: Cash has improved year-on-year but remains well below the 2023 peak. Think of this as hydration: adequate for now, but reserves are far lower than they were two years ago.
4. Leverage — Secured Long-Term Debt vs Equity - Long-term bank loans: £229,937 | Shareholders’ funds: £25,269 - Interpretation: Secured debt is roughly nine times the equity cushion. The bank loan is secured against the company’s assets. This is a high gearing ratio, comparable to a patient relying heavily on medication to maintain stability; any change in loan terms or asset values could create pressure.
5. Working Capital — Net Current Assets - 2025: £233,001 | 2024: £324,393 - Interpretation: The funds available for day-to-day operations have fallen by about 28%. This reduces flexibility to handle unexpected costs.
6. Creditor Behaviour - Trade creditors: £209,257 (2025) vs £90,197 (2024) - Interpretation: Amounts owed to suppliers have more than doubled. This can indicate the company is stretching payments to preserve cash, which may strain supplier relationships if not managed.
7. Filing Compliance - Accounts and confirmation statement are up to date and not overdue. - Interpretation: Good corporate hygiene; no immediate regulatory pressure.
Diagnosis and Prognosis
Diagnosis: The company is in a state of “solvent but strained” financial health. It is not insolvent, and its short-term ability to pay bills is intact. However, the sharp fall in retained earnings, high dependence on a secured bank loan, and rising trade creditors point to underlying weakness. The balance sheet shows a large proportion of assets tied up in stock (£251,476), with relatively modest fixed assets (£22,205).
The accounts state the company is entitled to audit exemption and has prepared filleted accounts under the small companies regime, so a profit and loss account is not publicly available. Without that detail, it is difficult to confirm whether the equity decline is due to trading losses, dividends, or other distributions.
Symptoms analysis: - Positive: Cash reserves are positive; trade debtors have fallen (from £30,432 to £5,292), suggesting improved collection from customers; depreciation on fixed assets is being managed. - Concerning: Equity has nearly been wiped out in one year; long-term debt remains static at £229,937 while equity shrinks; stock levels are unchanged at £251,476, tying up cash; average employee numbers fell from 4 to 3.
Prognosis: Guarded. If the company can restore profitability, convert stock to cash, and reduce reliance on the secured loan, it can stabilise. If trading losses continue or the lender demands repayment, the thin equity base offers little protection. The next 12 months are critical.
Recommendations
- Produce monthly management accounts, including a profit and loss account, to identify why shareholders’ funds fell by approximately £93,000 in the year.
- Engage with the secured lender to review repayment terms for the £229,937 bank loan and assess whether refinancing is possible before any repayment pressure arises.
- Review the £251,476 stock/work-in-progress balance to ensure it is realisable and not obsolete; prioritise converting unsold stock into cash.
- Negotiate agreed payment plans with trade creditors to prevent the £209,257 balance from triggering supplier pressure or legal action.
- Maintain the current cash buffer of £125,040 and avoid further distributions until equity is rebuilt.
- Continue meeting all filing deadlines to avoid penalties and preserve credibility with lenders and suppliers.